Consolidated Balance Sheet

Oncolys BioPharma Inc. - Filing #7712865

Concept As at
2017-03-31
As at
2016-12-31
Consolidated balance sheet
Balance sheet
Assets
Current assets
Cash and deposits
2,657,923,000 JPY
2,564,045,000 JPY
Accounts receivable - trade
15,000,000 JPY
66,351,000 JPY
Accounts receivable - other
21,228,000 JPY
3,436,000 JPY
Merchandise and finished goods
12,504,000 JPY
13,403,000 JPY
Prepaid expenses
16,441,000 JPY
17,474,000 JPY
Raw materials and supplies
1,608,000 JPY
1,715,000 JPY
Other
154,000 JPY
34,000 JPY
Current assets
2,790,083,000 JPY
2,746,518,000 JPY
Non-current assets
Property, plant and equipment
Buildings, net
JPY
JPY
Property, plant and equipment
2,538,000 JPY
JPY
Investments and other assets
Investment securities
340,454,000 JPY
351,940,000 JPY
Investments in capital
100,000 JPY
100,000 JPY
Other
19,000 JPY
19,000 JPY
Investments and other assets
381,991,000 JPY
393,795,000 JPY
Long-term prepaid expenses
1,492,000 JPY
1,582,000 JPY
Non-current assets
384,529,000 JPY
393,795,000 JPY
Assets
3,174,613,000 JPY
3,140,313,000 JPY
Liabilities
Current liabilities
Short-term borrowings
60,000,000 JPY
63,202,000 JPY
Deposits received
6,258,000 JPY
5,155,000 JPY
Accounts payable - other
47,820,000 JPY
89,739,000 JPY
Income taxes payable
10,224,000 JPY
24,634,000 JPY
Lease liabilities
10,662,000 JPY
9,949,000 JPY
Accrued expenses
9,690,000 JPY
11,779,000 JPY
Advances received
86,000 JPY
388,000 JPY
Current liabilities
144,742,000 JPY
204,849,000 JPY
Non-current liabilities
Long-term borrowings
300,000,000 JPY
300,000,000 JPY
Lease liabilities
14,272,000 JPY
15,297,000 JPY
Non-current liabilities
317,153,000 JPY
318,080,000 JPY
Liabilities
461,896,000 JPY
522,929,000 JPY
Liabilities and net assets
Shareholders' equity
2,714,822,000 JPY
2,605,149,000 JPY
Share capital
5,267,091,000 JPY
5,090,981,000 JPY
Capital surplus
5,259,591,000 JPY
5,083,481,000 JPY
Retained earnings
-7,811,860,000 JPY
-7,569,313,000 JPY
Valuation and translation adjustments
-19,856,000 JPY
-8,370,000 JPY
Valuation difference on available-for-sale securities
-19,856,000 JPY
-8,370,000 JPY
Share acquisition rights
17,751,000 JPY
20,604,000 JPY
Net assets
2,712,717,000 JPY
2,617,383,000 JPY
Liabilities and net assets
3,174,613,000 JPY
3,140,313,000 JPY
Net assets
Shareholders' equity
Valuation and translation adjustments

Talk to a Data Expert

Have a question? We'll get back to you promptly.